Home›Trial›NCT06129240
NCT06129240Recruiting

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

Study Summary

Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.

Conditions
Pulmonary HypertensionInterstitial Lung Disease
Interventions / Drugs
LIQ861
View on ClinicalTrials.gov ↗
Sponsor
LQDA
Liquidia Technologies
Pulmonary
D43/100
Study Details
Enrollment80 participants
Primary Completion2027-07-31
Lead SponsorLiquidia Technologies, Inc.
Data Retrieved2026-10-14
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Primary completion: 2027-07-31
Enrolled: 80 participants
Sponsor Catalyst Profile

Liquidia Technologies (LQDA) is the sponsoring company for this trial. BiotechSign currently grades this company D (43/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

LQDA Full Pipeline →All Companies →
Other Trials from Liquidia Technologies
NCT03992755Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safe…(PHASE3)NCT04691154A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With…(PHASE3)
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.
© 2026 BiotechSign — AI-powered biotech catalyst intelligence